Page 442 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C3.2. KQ3 multivariable analyses (continued)
Author Factors Data source Duration Analyzed Population WW/AS Methods Results as described in paper
yr sample characteristics definitions
PMI
Meng 167 Social, CaPSURE 1989- 457 Men with Not Cox Of the 457 men initially treated
2003 clinical, 2001 localized explicitly proportional with WW, 188 (41%) received
14634396 delivery prostate cancer provided hazards subsequent active treatment at a
system who chose WW models with median of 1.7 yr.
as the initial backward
treatment within stepwise 1. Disease risk (D’Amico),
9 mo of the dx, regression - High vs. low risk of prostate
no active (stay criteria cancer: HR=2.75 (CI 1.84, 4.12);
treatment within p<0.1) for P<.0001
6 months of active - Intermediate vs. low risk of
initiating WW treatment prostate cancer: HR=1.51 (CI
and >6 months (WW 1.05, 2.07); P=.028
of study interruption) 2. Age,
followup - 65-74 vs. <65, HR=0.70 (CI
0.41, 1.18); P=0.18
- ≥75 vs. <65. HR=0.57 (CI 0.33,
0.96); P=0.035
3. Education level,
- not college graduate vs. college
graduate, HR=0.66 (CI 0.46, 0.94);
P=0.021
- unknown vs. college graduate,
HR=0.68 (CI 0.42,1.10); P=0.11
Koppie 168 Clinical CaPSURE NR 329 Men with No therapy Cox Cox regression using only baseline
2000 biopsy- within 9 mo proportional variables:
10840429 confirmed of dx hazards 1. age,
prostate cancer regression, - 65-74 yr vs. <65 yr, HR=0.374
who elected including an (CI 0.179, 0.784); P=0.009
WW as their analysis of - ≥65 yr vs. <65 yr, HR=0.336
initial treatment. time- (CI 0.166, 0.679); P=0.002
dependent 2. clinical T stage at dx,
predictors - T2 vs. T1, HR =1.833 (CI 1.123,
time-to-active 2.992); P=0.015
treatment/ - T3-T4 vs. T1, HR=1.149 (CI
WW 0.440, 3.002); P=0.777
interruption 3. PSA at dx, ng/ml
- 4.1-10.0 vs. 0-4.0, HR=3.064
(CI 1.352, 6.944); P=0.007
- 10.1-20.0 vs. 0-4.0, HR=3.680

C-139